Article and Video CATEGORIES
Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University
Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute
En esta serie de videos, los Dres. Luis Raez, Estalemari Rodríguez y Ticiana Leal tienen conversaciones sinceras sobre el cáncer y el COVID-19.
En este tiempo continuo de distanciamiento social y limitación de la exposición clínica, los médicos se sentaron a discutir algunas de las preguntas que todos escuchamos con respecto a estos tiempos sin precedentes y cómo afectan principalmente a los pacientes con cáncer.
En este video, la discusión gira en torno al uso de la vacuna COVID-19 en pacientes con cáncer.
Gracias a #Exelixis y #Merck por su apoyo a este programa.
Para unirse a la conversación, visite https://cancergrace.org/forum.
***********
In this video series Drs. Luis Raez, Estalemari Rodriguez, and Ticiana Leal have candid discussions regarding cancer and COVID-19.
In this continued time of social distancing and limiting clinic exposure, the doctors sat down to discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.
In this video, the discussion is surrounding the use of the COVID-19 Vaccine in cancer patients.
Thanks to #Exelixis and #Merck for their support of this program.
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…
That's beautiful Linda. Thank you,